Jefferies Reiterates on Dynavax Technologies Awaiting Initiation of HBV-23 Safety Trial

In a report published Friday, Jefferies analyst Thomas Wei reiterated a Buy rating and $3.00 price target on Dynavax Technologies (NASDAQ: DVAX ). In the report, Jefferies noted, “DVAX had recently provided an update on its Heplisav safety study, HBV-23, the critical trial necessary to address the FDA's complete response